Prokaryotics, founded by a team of former senior scientists from Merck & Co., Inc., including the head of the Antimicrobial Early Discovery Unit, is a biopharmaceutical start-up focused on antibiotic discovery. The company's core mission is to develop innovative therapeutics to combat multidrug-resistant bacteria and address the global crisis of antibiotic resistance. Prokaryotics leverages several novel antibiotic programs licensed from Merck, aiming to optimize these early-stage programs for effective clinical applications.
Notable affiliated individuals include former senior scientists from Merck, who bring extensive expertise in antimicrobial discovery. Prokaryotics has garnered attention for its strategic approach to tackling antibiotic resistance, a critical public health issue. The company's impact lies in its potential to deliver groundbreaking antibiotics that could significantly reduce the threat of resistant bacterial infections, thereby improving global health outcomes.
